modest weight loss (12 kg) primarily through appetite suppression and reduced caloric intake Months 26 : Accelerated weight loss phase
The growing global prevalence of type 2 diabetes and obesity has significantly increased demand for GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide, which are known for their ability to manage blood glucose levels, support weight loss, and improve cardiovascular outcomes
Novo Nordisk finished January-September 2025 with DKK 95.264 billion ($14.907 billion) for semaglutide in adult type 2 diabetes (marketed as Ozempic ), up only 10% from DKK 86.489 billion ($13.533 billion) in January-September 2024
Fruit-Based Sorbet: Sorbets are naturally fat-free
IsHycomin Injectionsafe while breastfeeding
The most commonly reported initial effect in clinical trials is appetite suppression